{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:21:48Z","timestamp":1793726508028,"version":"4.6.1"},"reference-count":58,"publisher":"Pleiades Publishing Ltd","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochemistry Moscow"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      To date, the molecular mechanisms of the common neurodegenerative disorder Parkinson\u2019s disease (PD) are unknown and, as a result, there is no neuroprotective therapy that may stop or slow down the process of neuronal cell death. The aim of the current study was to evaluate the prospects of using the mTOR molecule as\u00a0a\u00a0potential target for PD therapy due to the dose-dependent effect of mTOR kinase activity inhibition on cellular parameters associated with, PD pathogenesis. The study used peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line. As a result, we have for the first time showed that inhibition of mTOR by Torin1 only at a concentration of 100\u00a0nM affects the level of the lysosomal enzyme glucocerebrosidase (GCase), encoded by the\n                      <jats:italic>GBA1<\/jats:italic>\n                      gene. Mutations in GBA1 are considered a high-risk factor for PD development. This concentration led a decrease in pathological phosphorylated alpha-synuclein (Ser129), an increase in its stable tetrameric form with no changes in the lysosomal enzyme activities and concentrations of lysosphingolipids. Our findings suggest that inhibition of the mTOR protein kinase could be a promising approach for developing therapies for PD, particularly for GBA1-associated PD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1134\/s0006297924070113","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T13:04:02Z","timestamp":1723467842000},"page":"1300-1312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dose-Dependent Alterations of Lysosomal Activity and Alpha-Synuclein in Peripheral Blood Monocyte-Derived Macrophages and SH-SY5Y Neuroblastoma Cell Line by upon Inhibition of MTOR Protein Kinase \u2013 Assessment of the Prospects of Parkinson\u2019s Disease Therapy"],"prefix":"10.1134","volume":"89","author":[{"given":"Anastasia I.","family":"Bezrukova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina S.","family":"Basharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina V.","family":"Baydakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina Y.","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya","family":"N.\u00a0Pchelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana S.","family":"Usenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"137","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"2720_CR1","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1111\/febs.14607","volume":"285","author":"D.\u00a0J. Surmeier","year":"2018","unstructured":"Surmeier, D.\u00a0J. (2018) Determinants of dopaminergic neuron loss in Parkinson\u2019s disease, FEBS\u00a0J., 285, 3657-3668, \nhttps:\/\/doi.org\/10.1111\/febs.14607.","journal-title":"FEBS\u00a0J."},{"key":"2720_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"H. R. Morris","year":"2024","unstructured":"Morris, H. R., Spillantini, M. G., Sue, C. M., and Williams-Gray, C.\u00a0H. (2024) The\u00a0pathogenesis of Parkinson\u2019s disease, Lancet, 403, 293-304, \nhttps:\/\/doi.org\/10.1016\/S0140-6736(23)01478-2.","journal-title":"Lancet"},{"key":"2720_CR3","doi-asserted-by":"publisher","unstructured":"Kouli, A, Torsney, K. M., and Kuan, W.\u00a0L. (2018) Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis, in Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects (Stoker, T.\u00a0B., and Greenland, J.\u00a0C., eds) Brisbane (AU), Codon Publications, Chap.\u00a01, \nhttps:\/\/doi.org\/10.15586\/codonpublications.parkinsonsdisease.2018.ch1.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"2720_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009357","volume":"2","author":"M. A. Lynch-Day","year":"2012","unstructured":"Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., and Klionsky, D.\u00a0J. (2012) The\u00a0role of autophagy in Parkinson\u2019s disease, Cold Spring Harb. Perspect. Med., 2, a009357, \nhttps:\/\/doi.org\/10.1101\/cshperspect.a009357.","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2720_CR5","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","volume":"432","author":"X. Hou","year":"2020","unstructured":"Hou, X., Watzlawik, J. O., Fiesel, F. C., and Springer, W. (2020) Autophagy in Parkinson\u2019s disease, J.\u00a0Mol. Biol., 432, 2651-2672, \nhttps:\/\/doi.org\/10.1016\/j.jmb.2020.01.037.","journal-title":"J.\u00a0Mol. Biol."},{"key":"2720_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biom13101435","volume":"13","author":"L. Nechushtai","year":"2023","unstructured":"Nechushtai, L., Frenkel, D., and Pinkas-Kramarski, R. (2023) Autophagy in Parkinson\u2019s disease, Biomolecules, 13, 1435, \nhttps:\/\/doi.org\/10.3390\/biom13101435.","journal-title":"Biomolecules"},{"key":"2720_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add0499","volume":"15","author":"M. R. Khan","year":"2024","unstructured":"Khan, M. R., Yin, X., Kang, S.-U., Mitra, J., Wang, H., Ryu, T., Brahmachari, S., Karuppagounder, S. S., Kimura, Y., Jhaldiyal, A., Kim, H. H., Gu, H., Chen, R., Redding-Ochoa, J., Troncoso, J., Na, C. H., Ha, T., Dawson, V. L., and Dawson, T. M. (2024) Enhanced mTORC1 signaling and protein synthesis in pathologic \u03b1-synuclein cellular and animal models of Parkinson\u2019s disease, Sci. Transl. Med., 15, eadd0499, \nhttps:\/\/doi.org\/10.1126\/scitranslmed.add0499.","journal-title":"Sci. Transl. Med."},{"key":"2720_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-016-8417-7","volume":"19","author":"A. Lan","year":"2017","unstructured":"Lan, A., Chen, J., Zhao, Y., Chai, Z., and Hu, Y. (2017) mTOR signaling in Parkinson\u2019s disease, Neuromol. Med., 19, 1-10, \nhttps:\/\/doi.org\/10.1007\/s12017-016-8417-7.","journal-title":"Neuromol. Med."},{"key":"2720_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512164","volume":"24","author":"T. Usenko","year":"2023","unstructured":"Usenko, T., Bezrukova, A., Rudenok, M.\u00a0M., Basharova, K., Shadrina, M.\u00a0I., Slominsky, P.\u00a0A., Zakharova, E., and Pchelina, S. (2023) Whole transcriptome analysis of substantia nigra in mice with MPTP-induced parkinsonism bearing defective glucocerebrosidase activity, Int.\u00a0J. Mol. Sci., 24, 12164, \nhttps:\/\/doi.org\/10.3390\/ijms241512164.","journal-title":"Int.\u00a0J. Mol. Sci."},{"key":"2720_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/genes12101545","volume":"12","author":"T. Usenko","year":"2021","unstructured":"Usenko, T., Bezrukova, A., Basharova, K., Panteleeva, A., Nikolaev, M., Kopytova, A., Miliukhina, I., Emelyanov, A., Zakharova, E., and Pchelina, S. (2021) Comparative transcriptome analysis in monocyte-derived macrophages of asymptomatic GBA mutation carriers and patients with GBA-associated Parkinson\u2019s disease, Genes (Basel), 12, 1545, \nhttps:\/\/doi.org\/10.3390\/genes12101545.","journal-title":"Genes (Basel)"},{"key":"2720_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112180","volume":"42","author":"H. Bogetofte","year":"2023","unstructured":"Bogetofte, H., Ryan, B. J., Jensen, P., Schmidt, S.\u00a0I., Vergoossen, D.\u00a0L.\u00a0E., Barnkob, M. B., Kiani, L. N., Chughtai, U., Heon-Roberts, R., Caiazza, M. C., McGuinness, W., M\u00e1rquez-G\u00f3mez, R., Vowles, J., Bunn, F. S., Brandes, J., Kilfeather, P., Connor, J. P., Fernandes, H. J. R., Caffrey, T. M., Meyer, M., Cowley, S. A., Larsen, M. R., and Wade-Martins, R. (2023) Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson\u2019s disease GBA-N370S dopamine neurons, Cell Rep., 42, 112180, \nhttps:\/\/doi.org\/10.1016\/j.celrep.2023.112180.","journal-title":"Cell Rep."},{"key":"2720_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1152503","volume":"17","author":"F. Mubariz","year":"2023","unstructured":"Mubariz, F., Saadin, A., Lingenfelter, N., Sarkar, C., Banerjee, A., Lipinski, M.\u00a0M., and Awad,\u00a0O. (2023) Deregulation of mTORC1\u2013TFEB axis in human IPSC model of GBA1-associated Parkinson\u2019s disease, Front. Neurosci., 17, 1152503, \nhttps:\/\/doi.org\/10.3389\/fnins.2023.1152503.","journal-title":"Front. Neurosci."},{"key":"2720_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117628","volume":"322","author":"L. Yu","year":"2024","unstructured":"Yu, L., Hu, X., Xu, R., Zhao, Y., Xiong, L., Ai, J., Wang, X., Chen, X., Ba, Y., Xing, Z., Guo, C., Mi, S., and Wu, X. (2024) Piperine promotes PI3K\/AKT\/mTOR-mediated gut-brain autophagy to degrade \u03b1-synuclein in Parkinson\u2019s disease rats, J.\u00a0Ethnopharmacol., 322, 117628, \nhttps:\/\/doi.org\/10.1016\/j.jep.2023.117628.","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"2720_CR14","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.21037\/apm-20-1096","volume":"10","author":"G. Zhang","year":"2021","unstructured":"Zhang, G., Yin, L., Luo, Z., Chen, X., He, Y., Yu, X., Wang, M., Tian, F., and Luo, H. (2021) Effects and potential mechanisms of rapamycin on MPTP-induced acute Parkinson\u2019s disease in mice, Ann. Palliat. Med., 10, 2889-2897, \nhttps:\/\/doi.org\/10.21037\/apm-20-1096.","journal-title":"Ann. Palliat. Med."},{"key":"2720_CR15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","volume":"11","author":"E. Sidransky","year":"2012","unstructured":"Sidransky, E., and Lopez, G. (2012) The\u00a0link between the GBA gene and parkinsonism, Lancet Neurol., 11, 986-998, \nhttps:\/\/doi.org\/10.1016\/S1474-4422(12)70190-4.","journal-title":"Lancet Neurol."},{"key":"2720_CR16","doi-asserted-by":"publisher","first-page":"267.e7","DOI":"10.1016\/j.neurobiolaging.2018.06.027","volume":"71","author":"A.\u00a0K. Emelyanov","year":"2018","unstructured":"Emelyanov, A.\u00a0K., Usenko, T.\u00a0S., Tesson, C., Senkevich, K.\u00a0A., Nikolaev, M.\u00a0A., Miliukhina, I. V., Kopytova, A. E., Timofeeva, A. A., Yakimovsky, A. F., Lesage, S., Brice, A., and Pchelina, S. N. (2018) Mutation analysis of Parkinson\u2019s disease genes in a Russian data set, Neurobiol. Aging, 71, 267.e7-267.e10, \nhttps:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.06.027.","journal-title":"Neurobiol. Aging"},{"key":"2720_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00361-4","volume":"8","author":"J. Xu","year":"2022","unstructured":"Xu, J., Ao, Y.-L., Huang, C., Song, X., Zhang, G., Cui, W., Wang, Y., Zhang, X. Q., and Zhang, Z. (2022) Harmol promotes \u03b1-synuclein degradation and improves motor impairment in Parkinson\u2019s models via regulating autophagy-lysosome pathway, NPJ Parkinsons Dis., 8, 100, \nhttps:\/\/doi.org\/10.1038\/s41531-022-00361-4.","journal-title":"NPJ Parkinsons Dis."},{"key":"2720_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.175","volume":"5","author":"B. I. P\u00e9rez-Revuelta","year":"2014","unstructured":"P\u00e9rez-Revuelta, B. I., Hettich, M. M., Ciociaro, A., Rotermund, C., Kahle, P.\u00a0J., Krauss, S., and Di Monte, D. A. (2014) Metformin lowers Ser-129 phosphorylated \u03b1-synuclein levels via mTOR-dependent protein phosphatase\u00a02A activation, Cell Death Dis., 5, e1209, \nhttps:\/\/doi.org\/10.1038\/cddis.2014.175.","journal-title":"Cell Death Dis."},{"key":"2720_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030728","volume":"20","author":"Z. Zhu","year":"2019","unstructured":"Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S.\u00a0G., Liu, J., Wang, Z., Tong, B. C., Song, J., Lu, J., Cheung, K. H., and Li, M. (2019) Balancing mTOR signaling and autophagy in the treatment of Parkinson\u2019s disease, Int.\u00a0J. Mol. Sci., 20, 728, \nhttps:\/\/doi.org\/10.3390\/ijms20030728.","journal-title":"Int.\u00a0J. Mol. Sci."},{"key":"2720_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0149-0","volume":"12","author":"H. Xicoy","year":"2017","unstructured":"Xicoy, H., Wieringa, B., and Martens, G. J. M. (2017) The\u00a0SH-SY5Y cell line in Parkinson\u2019s disease research: a systematic review, Mol. Neurodegener., 12, 10, \nhttps:\/\/doi.org\/10.1186\/s13024-017-0149-0.","journal-title":"Mol. Neurodegener."},{"key":"2720_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","volume":"84","author":"A. E. Kopytova","year":"2021","unstructured":"Kopytova, A. E., Rychkov, G. N., Nikolaev, M. A., Baydakova, G.\u00a0V., Cheblokov, A.\u00a0A., Senkevich, K. A., Bogdanova, D. A., Bolshakova, O. I., Miliukhina, I. V., Bezrukikh, V. A., Salogub, G. N., Sarantseva, S. V., Usenko, T. C., Zakharova, E. Y., Emelyanov, A. K., and Pchelina, S. N. (2021) Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and parkinsonism, Parkinsonism Relat. Disord., 84, 112-121, \nhttps:\/\/doi.org\/10.1016\/j.parkreldis.2021.02.003.","journal-title":"Parkinsonism Relat. Disord."},{"key":"2720_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008659","volume":"6","author":"E. Aflaki","year":"2014","unstructured":"Aflaki, E., Stubblefield, B.\u00a0K., Maniwang, E., Lopez, G., Moaven, N., Goldin, E., Marugan, J., Patnaik, S., Dutra, A., Southall, N., Zheng, W., Tayebi, N., and Sidransky, E. (2014) Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs, Sci. Transl. Med., 6, 240ra73, \nhttps:\/\/doi.org\/10.1126\/scitranslmed.3008659.","journal-title":"Sci. Transl. Med."},{"key":"2720_CR23","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.038596","volume":"12","author":"R. A. Brown","year":"2019","unstructured":"Brown, R. A., Voit, A., Srikanth, M.\u00a0P., Thayer, J.\u00a0A., Kingsbury, T.\u00a0J., Jacobson, M. A., Lipinski, M. M., Feldman, R. A., and Awad, O. (2019) mTOR hyperactivity mediates lysosomal dysfunction in Gaucher\u2019s disease IPSC-neuronal cells, Dis. Model Mech., 12, dmm038596, \nhttps:\/\/doi.org\/10.1242\/dmm.038596.","journal-title":"Dis. Model Mech."},{"key":"2720_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.25557\/2073-7998.2022.12.26-29","volume":"21","author":"T. S. Usenko","year":"2022","unstructured":"Usenko, T. S., Basharova, K. S., Bezrukova, A. I., Nikolaev, M. A., Milyukhina, I. V., Baidakova, G. V., Zakharova, E. Yu., Pchelina, S. N. (2022) Selective inhibition of LRRK2 kinase activity for treatment of Parkinson's disease [in Russian], Meditsinskaya genetika, 21, 26-29, \nhttps:\/\/doi.org\/10.25557\/2073-7998.2022.12.26-29.","journal-title":"Meditsinskaya genetika"},{"key":"2720_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109105","volume":"24","author":"A. E. Kopytova","year":"2023","unstructured":"Kopytova, A. E., Rychkov, G. N., Cheblokov, A. A., Grigor\u2019eva, E. V., Nikolaev, M.\u00a0A., Yarkova, E. S., Sorogina, D. A., Ibatullin, F. M., Baydakova, G. V., Izyumchenko, A. D., Bogdanova, D. A., Boitsov, V. M., Rybakov, A. V., Miliukhina, I. V., Bezrukikh, V. A., Salogub, G. N., Zakharova, E. Y., Pchelina, S. N., and Emelyanov, A. K. (2023) Potential binding sites of pharmacological chaperone NCGC00241607 on mutant beta-glucocerebrosidase and its efficacy on patient-derived cell cultures in Gaucher and Parkinson\u2019s disease, Int.\u00a0J. Mol. Sci., 24, 9105, \nhttps:\/\/doi.org\/10.3390\/ijms24109105.","journal-title":"Int.\u00a0J. Mol. Sci."},{"key":"2720_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/3830861","author":"C. Norradee","year":"2023","unstructured":"Norradee, C., Khwanraj, K., Balit, T., and Dharmasaroja, P. (2023) Evaluation of the combination of metformin and rapamycin in an MPP+-treated SH-SY5Y model of Parkinson\u2019s disease, Adv. Pharmacol. Pharm. Sci., 3830861, \nhttps:\/\/doi.org\/10.1155\/2023\/3830861.","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"2720_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2019.105414","volume":"135","author":"M.-A. Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez, M.-A., Rodr\u00edguez, J.-L., Lopez-Torres, B., Mart\u00ednez, M., Mart\u00ednez-Larra\u00f1aga, M.-R., Maximiliano, J. E., Anad\u00f3n, A., and Ares, I. (2020) Use of human neuroblastoma SH-SY5Y cells to evaluate glyphosate-induced effects on oxidative stress, neuronal development and cell death signaling pathways, Environ. Int., 135, 105414, \nhttps:\/\/doi.org\/10.1016\/j.envint.2019.105414.","journal-title":"Environ. Int."},{"key":"2720_CR28","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/mds.27393","volume":"33","author":"S. Pchelina","year":"2018","unstructured":"Pchelina, S., Baydakova, G., Nikolaev, M., Senkevich, K., Emelyanov, A., Kopytova, A., Miliukhina, I., Yakimovskii, A., Timofeeva, A., Berkovich, O., Fedotova, E., Illarioshkin, S., and Zakharova, E. (2018) Blood lysosphingolipids accumulation in patients with Parkinson\u2019s disease with glucocerebrosidase\u00a01 mutations, Mov. Disord., 33, 1325-1330, \nhttps:\/\/doi.org\/10.1002\/mds.27393.","journal-title":"Mov. Disord."},{"key":"2720_CR29","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s12035-021-02688-0","volume":"59","author":"T. S. Usenko","year":"2022","unstructured":"Usenko, T. S., Senkevich, K. A., Bezrukova, A.\u00a0I., Baydakova, G. V., Basharova, K.\u00a0S., Zhuravlev, A. S., Gracheva, E. V., Kudrevatykh, A. V., Miliukhina, I. V., Krasakov, I. V., Khublarova, L. A., Fursova, I. V., Zakharov, D. V., Timofeeva, A. A., Irishina, Y. A., Palchikova, E. I., Zalutskaya, N. M., Emelyanov, A. K., Zakharova, E. Y., and Pchelina, S. N. (2022) Impaired sphingolipid hydrolase activities in dementia with Lewy bodies and multiple system atrophy, Mol. Neurobiol., 59, 2277-2287, \nhttps:\/\/doi.org\/10.1007\/s12035-021-02688-0.","journal-title":"Mol. Neurobiol."},{"key":"2720_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14010030","volume":"14","author":"T. Usenko","year":"2024","unstructured":"Usenko, T., Bezrukova, A., Basharova, K., Baydakova, G., Shagimardanova, E., Blatt, N., Rizvanov, A., Limankin, O., Novitskiy, M., Shnayder, N., Izyumchenko, A., Nikolaev, M., Zabotina, A., Lavrinova, A., Kulabukhova, D., Nasyrova, R., Palchikova, E., Zalutskaya, N., Miliukhina, I., Barbitoff, Y., Glotov, O., Glotov, A., Taraskina, A., Neznanov, N., Zakharova, E., and Pchelina, S. (2024) Altered sphingolipid hydrolase activities and alpha-synuclein level in late-onset schizophrenia, Metabolites, 14, 30, \nhttps:\/\/doi.org\/10.3390\/metabo14010030.","journal-title":"Metabolites"},{"key":"2720_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082415","volume":"8","author":"T. Tsukuba","year":"2013","unstructured":"Tsukuba, T., Yanagawa, M., Kadowaki, T., Takii, R., Okamoto, Y., and Yamamoto, K.\u00a0(2013) Cathepsin e deficiency impairs autophagic proteolysis in macrophages, PLoS One, 8, e82415, \nhttps:\/\/doi.org\/10.1371\/journal.pone.0082415.","journal-title":"PLoS One"},{"key":"2720_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147639","volume":"882","author":"T. S. Usenko","year":"2023","unstructured":"Usenko, T. S., Senkevich, K. A., Basharova, K. S., Bezrukova, A. I., Baydakova, G. V., Tyurin, A. A., Beletskaya, M. V., Kulabukhova, D. G., Grunina, M. N., Emelyanov, A. K., Miliukhina, I. V., Timofeeva, A. A., Zakharova, E. Y., and Pchelina, S. N. (2023) LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson\u2019s disease, Gene, 882, 147639, \nhttps:\/\/doi.org\/10.1016\/j.gene.2023.147639.","journal-title":"Gene"},{"key":"2720_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2016.10.039","volume":"636","author":"S. Pchelina","year":"2017","unstructured":"Pchelina, S., Emelyanov, A., Baydakova, G., Andoskin, P., Senkevich, K., Nikolaev, M., Miliukhina, I., Yakimovskii, A., Timofeeva, A., Fedotova, E., Abramycheva, N., Usenko, T., Kulabukhova, D., Lavrinova, A., Kopytova, A., Garaeva, L., Nuzhnyi, E., Illarioshkin, S., and Zakharova, E. (2017) Oligomeric \u03b1-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson\u2019s disease, Neurosci. Lett., 636, 70-76, \nhttps:\/\/doi.org\/10.1016\/j.neulet.2016.10.039.","journal-title":"Neurosci. Lett."},{"key":"2720_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112399","volume":"9","author":"A. Navarro-Romero","year":"2020","unstructured":"Navarro-Romero, A., Montpey\u00f3, M., and Martinez-Vicente, M. (2020) The\u00a0emerging role of the lysosome in Parkinson\u2019s disease, Cells, 9, 2399, \nhttps:\/\/doi.org\/10.3390\/cells9112399.","journal-title":"Cells"},{"key":"2720_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-981-15-4272-5_2","volume":"1207","author":"J. Lu","year":"2020","unstructured":"Lu, J., Wu, M., and Yue, Z. (2020) Autophagy and Parkinson\u2019s disease, Adv. Exp. Med. Biol., 1207, 21-51, \nhttps:\/\/doi.org\/10.1007\/978-981-15-4272-5_2.","journal-title":"Adv. Exp. Med. Biol."},{"key":"2720_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.921314","volume":"10","author":"I. Sanchez-Mirasierra","year":"2022","unstructured":"Sanchez-Mirasierra, I., Ghimire, S., Hernandez-Diaz, S., and Soukup, S.\u00a0F. (2022) Targeting macroautophagy as a therapeutic opportunity to treat Parkinson\u2019s disease, Front. Cell Dev. Biol., 10, 921314, \nhttps:\/\/doi.org\/10.3389\/fcell.2022.921314.","journal-title":"Front. Cell Dev. Biol."},{"key":"2720_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0154-3","volume":"12","author":"T. E. Moors","year":"2017","unstructured":"Moors, T. E., Hoozemans, J. J. M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M. C., and van de Berg, W. D. J. (2017) Therapeutic potential of autophagy-enhancing agents in Parkinson\u2019s disease, Mol. Neurodegener., 12, 11, \nhttps:\/\/doi.org\/10.1186\/s13024-017-0154-3.","journal-title":"Mol. Neurodegener."},{"key":"2720_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040621","volume":"12","author":"R. Kinet","year":"2023","unstructured":"Kinet, R., and Dehay, B. (2023) Pathogenic aspects and therapeutic avenues of autophagy in Parkinson\u2019s disease, Cells, 12, 621, \nhttps:\/\/doi.org\/10.3390\/cells12040621.","journal-title":"Cells"},{"key":"2720_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"R. A. Saxton","year":"2017","unstructured":"Saxton, R. A., and Sabatini, D. M. (2017) mTOR signaling in growth, metabolism, and disease, Cell, 168, 960-976, \nhttps:\/\/doi.org\/10.1016\/j.cell.2017.02.004.","journal-title":"Cell"},{"key":"2720_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V. Panwar","year":"2023","unstructured":"Panwar, V., Singh, A., Bhatt, M., Tonk, R.\u00a0K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., and Garg, M. (2023) Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease, Signal Transduct. Target Ther., 8, 375, \nhttps:\/\/doi.org\/10.1038\/s41392-023-01608-z.","journal-title":"Signal Transduct. Target Ther."},{"key":"2720_CR41","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1080\/14756366.2021.1955873","volume":"36","author":"Z. Chrienova","year":"2021","unstructured":"Chrienova, Z., Nepovimova, E., and Kuca, K. (2021) The\u00a0role of mTOR in age-related diseases, J.\u00a0Enzyme Inhib. Med. Chem., 36, 1678-1692, \nhttps:\/\/doi.org\/10.1080\/14756366.2021.1955873.","journal-title":"J.\u00a0Enzyme Inhib. Med. Chem."},{"key":"2720_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nbd.2015.03.014","volume":"84","author":"M. Perluigi","year":"2015","unstructured":"Perluigi, M., Di Domenico, F., and Butterfield, D.\u00a0A. (2015) mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy, Neurobiol. Dis., 84, 39-49, \nhttps:\/\/doi.org\/10.1016\/j.nbd.2015.03.014.","journal-title":"Neurobiol. Dis."},{"key":"2720_CR43","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s12035-017-0496-4","volume":"55","author":"R. Siracusa","year":"2018","unstructured":"Siracusa, R., Paterniti, I., Cordaro, M., Crupi, R., Bruschetta, G., Campolo, M., Cuzzocrea, S., and Esposito, E. (2018) Neuroprotective effects of temsirolimus in animal models of Parkinson\u2019s disease, Mol. Neurobiol., 55, 2403-2419, \nhttps:\/\/doi.org\/10.1007\/s12035-017-0496-4.","journal-title":"Mol. Neurobiol."},{"key":"2720_CR44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11481-012-9431-7","volume":"8","author":"T. F. Jiang","year":"2013","unstructured":"Jiang, T. F., Zhang, Y.\u00a0J., Zhou, H.\u00a0Y., Wang, H.\u00a0M., Tian, L.\u00a0P., Liu, J., Ding, J. Q., and Chen, S. D. (2013) Curcumin ameliorates the neurodegenerative pathology in A53T \u03b1-synuclein cell model of Parkinson\u2019s disease through the downregulation of mTOR\/P70S6K signaling and the recovery of macroautophagy, J.\u00a0Neuroimmune Pharmacol., 8, 356-369, \nhttps:\/\/doi.org\/10.1007\/s11481-012-9431-7.","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"2720_CR45","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2147\/NDT.S299810","volume":"17","author":"Z. N. Zhang","year":"2021","unstructured":"Zhang, Z. N., Hui, Z., Chen, C., Liang, Y., Tang, L.\u00a0L., Wang, S. L., Xu, C. C., Yang, H., Zhao, Y., and Zhang, J. S. (2021) Mechanism of autophagy regulation in MPTP-induced PD mice via the mTOR signaling pathway by echinacoside, Neuropsychiatr. Dis. Treat., 17, 1397-1411, \nhttps:\/\/doi.org\/10.2147\/NDT.S299810.","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"2720_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009313","volume":"5","author":"L. Crews","year":"2010","unstructured":"Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., and Masliah, E. (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of \u03b1-synucleinopathy, PLoS One, 5, e9313, \nhttps:\/\/doi.org\/10.1371\/journal.pone.0009313.","journal-title":"PLoS One"},{"key":"2720_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112820","volume":"208","author":"Y. Chen","year":"2020","unstructured":"Chen, Y., and Zhou, X. (2020) Research progress of mTOR inhibitors, Eur.\u00a0J. Med. Chem., 208, 112820, \nhttps:\/\/doi.org\/10.1016\/j.ejmech.2020.112820.","journal-title":"Eur.\u00a0J. Med. Chem."},{"key":"2720_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2322-6","volume":"11","author":"X.-X. Zhuang","year":"2020","unstructured":"Zhuang, X.-X., Wang, S.-F., Tan, Y., Song, J.-X., Zhu, Z., Wang, Z. Y., Wu, M. Y., Cai, C. Z., Huang, Z. J., Tan, J. Q., Su, H. X., Li, M., and Lu, J. H. (2020) Pharmacological enhancement of TFEB-mediated autophagy alleviated neuronal death in oxidative stress-induced Parkinson\u2019s disease models, Cell Death Dis., 11, 128, \nhttps:\/\/doi.org\/10.1038\/s41419-020-2322-6.","journal-title":"Cell Death Dis."},{"key":"2720_CR49","doi-asserted-by":"publisher","first-page":"12535","DOI":"10.1523\/JNEUROSCI.1920-10.2010","volume":"30","author":"B. Dehay","year":"2010","unstructured":"Dehay, B., Bov\u00e9, J., Rodr\u00edguez-Muela, N., Perier, C., Recasens, A., Boya, P., and Vila, M. (2010) Pathogenic lysosomal depletion in Parkinson\u2019s disease, J.\u00a0Neurosci., 30, 12535-12544, \nhttps:\/\/doi.org\/10.1523\/JNEUROSCI.1920-10.2010.","journal-title":"J.\u00a0Neurosci."},{"key":"2720_CR50","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"L. A. Robak","year":"2017","unstructured":"Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A.\u00a0G., Kraaij, R., Jankovic, J., International Parkinson\u2019s Disease Genomics Consortium (IPDGC), Heutink, P., and Shulman, J. M. (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease, Brain, 140, 3191-3203, \nhttps:\/\/doi.org\/10.1093\/brain\/awx285.","journal-title":"Brain"},{"key":"2720_CR51","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"K. Murphy","year":"2014","unstructured":"Murphy, K., Gysbers, A., Abbott, S., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., and Halliday, G. M. (2014) Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson\u2019s disease, Brain, 137, 834-848, \nhttps:\/\/doi.org\/10.1093\/brain\/awt367.","journal-title":"Brain"},{"key":"2720_CR52","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000201418","volume":"100","author":"L. Oftedal","year":"2023","unstructured":"Oftedal, L., Maple-Gr\u00f8dem, J., Dalen, I., Tysnes, O.-B., Pedersen, K.\u00a0F., Alves, G., and Lange, J. (2023) Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson disease, Neurology, 100, e388-e395, \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000201418.","journal-title":"Neurology"},{"key":"2720_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-015-0010-2","volume":"10","author":"D. Chiasserini","year":"2015","unstructured":"Chiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., Kurzawa-Akanbi, M., Chinnery, P. F., Morris, C. M., Calabresi, P., Parnetti, L., and Beccari, T. (2015) Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies, Mol. Neurodegener., 10, 15, \nhttps:\/\/doi.org\/10.1186\/s13024-015-0010-2.","journal-title":"Mol. Neurodegener."},{"key":"2720_CR54","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00415-020-09705-7","volume":"267","author":"S. A. Schneider","year":"2020","unstructured":"Schneider, S. A., and Alcalay, R. N. (2020) Precision medicine in Parkinson\u2019s disease: emerging treatments for genetic Parkinson\u2019s disease, J.\u00a0Neurol., 267, 860-869, \nhttps:\/\/doi.org\/10.1007\/s00415-020-09705-7.","journal-title":"J.\u00a0Neurol."},{"key":"2720_CR55","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"J. P. Anderson","year":"2006","unstructured":"Anderson, J. P., Walker, D. E., Goldstein, J. M., De Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P. S., Shen, X., Chataway, T., Schlossmacher, M. G., Seubert, P., Schenk, D., Sinha, S., Gai, W. P., and Chilcote, T. J. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic Lewy body disease, J.\u00a0Biol. Chem., 281, 29739-29752, \nhttps:\/\/doi.org\/10.1074\/jbc.M600933200.","journal-title":"J.\u00a0Biol. Chem."},{"key":"2720_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T. Bartels","year":"2011","unstructured":"Bartels, T., Choi, J.\u00a0G., and Selkoe, D.\u00a0J. (2011) \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation, Nature, 477, 107-111, \nhttps:\/\/doi.org\/10.1038\/nature10324.","journal-title":"Nature"},{"key":"2720_CR57","doi-asserted-by":"publisher","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","volume":"110","author":"M. Decressac","year":"2013","unstructured":"Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., and Bj\u00f6rklund, A. (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity, Proc. Natl. Acad. Sci. USA, 110, E1817-E1826, \nhttps:\/\/doi.org\/10.1073\/pnas.1305623110.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2720_CR58","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"J. L. Webb","year":"2003","unstructured":"Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., and Rubinsztein, D.\u00a0C. (2003) \u03b1-Synuclein is degraded by both autophagy and the proteasome, J.\u00a0Biol. Chem., 278, 25009-25013, \nhttps:\/\/doi.org\/10.1074\/jbc.M300227200.","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Biochemistry (Moscow)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297924070113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S0006297924070113","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297924070113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:22:34Z","timestamp":1773620554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S0006297924070113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2720"],"URL":"https:\/\/doi.org\/10.1134\/s0006297924070113","relation":{},"ISSN":["0006-2979","1608-3040"],"issn-type":[{"value":"0006-2979","type":"print"},{"value":"1608-3040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the procedures carried out in the research with participation of humans were in accordance with the ethical standards of the National Research Ethics Committee and with the Helsinki Declaration of 1964 and its subsequent changes or with comparable ethics standards. Informed voluntary consent was obtained from every participant of the study. The study was approved by the ethics committee of the Pavlov First Saint Petersburg State Medical University (protocol no.\u00a0275 dated of 09\/04\/2023). The authors declare that they no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}]}}